Ann: Company Update Post Commercial Launch, page-6

New Supply Agreement with Pharmacy Platform Pty Ltd The Company has reached a supply agreement with Pharmacy Platform Pty Ltd (PP). This leading pharmacy group is a recently merged group of pharmacies with more than 350 pharmacy members across Australia with an additional 800 pharmacy clients serviced through the new entity’s specialised business units. These pharmacies will initially just stock wheezo™ devices. Respiri continues to work alongside PP to develop an in-pharmacy asthma clinical program. This program will be run by pharmacists to help their asthma patients better understand how they can better manage their asthma and how wheezo™ fits into this regime. Every month approximately 2,000 patients with asthma visit a pharmacy and of these about 400 will have a discussion with their pharmacists about their asthma. In addition, Respiri continues to progress discussions for supply of wheezo devices with additional key pharmacy banner groups. The Company expects to update the market following the agreement of additional contracts. Respiri is pleased to confirm that a number of independent pharmacy groups are now stocking the device. Commencing Q1 CY2021, Respiri will provide investors a quarterly snapshot of unaudited wheezo™ unit sales and SaaS revenues with statutory quarterly cash flow reporting requirements.

certainly not sitting on their hands

more news before xmass

fda update